SE0103565D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE0103565D0
SE0103565D0 SE0103565A SE0103565A SE0103565D0 SE 0103565 D0 SE0103565 D0 SE 0103565D0 SE 0103565 A SE0103565 A SE 0103565A SE 0103565 A SE0103565 A SE 0103565A SE 0103565 D0 SE0103565 D0 SE 0103565D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
SE0103565A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103565A priority Critical patent/SE0103565D0/sv
Publication of SE0103565D0 publication Critical patent/SE0103565D0/sv
Priority to AT02718317T priority patent/ATE324886T1/de
Priority to NZ528284A priority patent/NZ528284A/en
Priority to JP2002578941A priority patent/JP2004525164A/ja
Priority to HU0303454A priority patent/HUP0303454A3/hu
Priority to KR10-2003-7012900A priority patent/KR20030087048A/ko
Priority to CNA028077474A priority patent/CN1536993A/zh
Priority to IL15795502A priority patent/IL157955A0/xx
Priority to EP02718317A priority patent/EP1381358B1/en
Priority to MXPA03008999A priority patent/MXPA03008999A/es
Priority to DE60211139T priority patent/DE60211139T2/de
Priority to CZ20032647A priority patent/CZ20032647A3/cs
Priority to ES02718317T priority patent/ES2261655T3/es
Priority to BR0208421-0A priority patent/BR0208421A/pt
Priority to US10/473,709 priority patent/US20040138299A1/en
Priority to EEP200300476A priority patent/EE200300476A/xx
Priority to CA002443040A priority patent/CA2443040A1/en
Priority to PL02365330A priority patent/PL365330A1/xx
Priority to SK1203-2003A priority patent/SK12032003A3/sk
Priority to PCT/GB2002/001439 priority patent/WO2002080902A1/en
Priority to IS6970A priority patent/IS6970A/is
Priority to NO20034386A priority patent/NO20034386L/no

Links

SE0103565A 2001-04-02 2001-10-25 Pharmaceutical formulation SE0103565D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
DE60211139T DE60211139T2 (de) 2001-04-02 2002-03-27 Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
ES02718317T ES2261655T3 (es) 2001-04-02 2002-03-27 Composicion farmaceutica solida que comprende 4'-ciano-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluiduro y pvp.
JP2002578941A JP2004525164A (ja) 2001-04-02 2002-03-27 ４−シアノ−トリフルオロ−３−（４−フルオロフェニルスルホニル）−２−ヒドロキシ−２−メチルプロピオノ−ｍ−トルイジドとＰＶＰを含む固体医薬組成物
HU0303454A HUP0303454A3 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
KR10-2003-7012900A KR20030087048A (ko) 2001-04-02 2002-03-27 4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물
CNA028077474A CN1536993A (zh) 2001-04-02 2002-03-27 包含4-氰基-三氟-n-[3-(4-氟苯磺酰基)-2-羟基-2-甲基丙酰基]-间甲苯胺和pvp的固体药物组合物
IL15795502A IL157955A0 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
EP02718317A EP1381358B1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
MXPA03008999A MXPA03008999A (es) 2001-04-02 2002-03-27 Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.
AT02718317T ATE324886T1 (de) 2001-04-02 2002-03-27 Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
CZ20032647A CZ20032647A3 (cs) 2001-04-02 2002-03-27 Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP
NZ528284A NZ528284A (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and PVP
BR0208421-0A BR0208421A (pt) 2001-04-02 2002-03-27 Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes
US10/473,709 US20040138299A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2hydroxy-methylpropiono-m toluidide and pvp
EEP200300476A EE200300476A (et) 2001-04-02 2002-03-27 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
CA002443040A CA2443040A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
PL02365330A PL365330A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
SK1203-2003A SK12032003A3 (sk) 2001-04-02 2002-03-27 Farmaceutická formulácia obsahujúca 4'-kyano-alfa', alfa', alfa'-trifluór-3-(4-fluórfenylsulfonyl)-2-hydroxy-2- metylpropiono-m-toluidín a PVP
IS6970A IS6970A (is) 2001-04-02 2003-09-29 Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
NO20034386A NO20034386L (no) 2001-04-02 2003-10-01 Fast farmasöytisk preparat omfattende 4-cyano-trifluor-3-(4- fluorfenylsulfonyl)-2-hydroksy-2-metylpropiono-m-toluidid og PVP

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0103565D0 true SE0103565D0 (sv) 2001-10-25

Family

ID=20285776

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103565A SE0103565D0 (sv) 2001-04-02 2001-10-25 Pharmaceutical formulation

Country Status (1)

Country Link
SE (1) SE0103565D0 (sv)

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
ITTO20010008A0 (it) Formulazione farmaceutica
FI20011478A0 (sv) Farmaceutisk komposition
PT1501534E (pt) Formulacoes farmaceuticas
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
DE50209245D1 (de) Neuroprotektives medikament
FI20022128A (sv) Farmaceutisk komposition
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
AR025867A1 (es) Formulacion portasdora farmaceutica
DE10291905D2 (de) Pharmazeutische Zusammensetzung
NO20015534D0 (no) Farmasöytisk blandeapparat
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de) Pharmazeutische Zusammensetzung
NO20041236L (no) Farmasoytisk formulering
FI20012242A0 (sv) Nya farmaceutiska föreningar
SE0102957D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation